FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2319325812> ?p ?o ?g. }

• W2319325812 endingPage "208" @default.
• W2319325812 startingPage "207" @default.
• W2319325812 abstract "First-line treatment of epithelial ovarian cancer includes debulking surgery and platinum/taxane combination chemotherapy. The initial rate of response is high, but most patients eventually die of a recurring disease. It has been suggested that green tea may be useful to maintain response to first-line therapy after primary treatment. The anticancer actions of green tea for ovarian cancer and other types of cancer have been attributed to the catechins, epigallocatechin gallate (EGCG) and epicatechin gallate. Double-brewed green tea (DBGT) is an EGCG-enriched tea that has significant antitumor activity. This trial was a 2-stage, single-arm, phase 2 study that assessed the efficacy and safety of DBGT as a maintenance treatment in women with advanced-stage ovarian cancer who were in complete clinical remission after cytoreductive surgery and first-line chemotherapy. The trial was conducted at a single center, the Centre Hospitalier Universitaire de Québec. All patients received 500 mL of DBGT to drink daily until recurrence or during a follow-up of 18 months. The primary study endpoint was the absence of recurrence at 18 months. The study used an intention-to-treat design. From 2007 to 2011, a total of 306 women were identified with International Federation of Gynecology and Obstetrics stage III to IV serous or endometrioid ovarian cancer who had undergone complete response after debulking surgery followed by 6 to 8 cycles of platinum/taxane chemotherapy. Of these women, 257 were not eligible and 23 were not evaluated for eligibility. Among the remaining 26 eligible women, 10 declined to participate and 16 enrolled in the first stage. According to the treatment plan, if 7 or fewer women were free of recurrence at 18 months of follow-up, the trial was stopped. Otherwise, enrollment would continue to a total of 46 patients. The trial was terminated after the first stage at 18 months of follow-up because only 5 of the 16 women were free of recurrence. The median adherence of the women to DBGT was 98.1% (interquartile range, 89.7%–100%). However, 6 women (37.5%) discontinued participation before the end of the follow-up. There was no severe toxicity. All adverse events were of grade 1. These data suggest that DBGT supplementation is not a promising maintenance therapy for women with advanced-stage ovarian cancer after first-line treatment." @default.
• W2319325812 created "2016-06-24" @default.
• W2319325812 creator A5001534228 @default.
• W2319325812 creator A5011724082 @default.
• W2319325812 creator A5022422757 @default.
• W2319325812 creator A5023267102 @default.
• W2319325812 creator A5023514231 @default.
• W2319325812 creator A5033540995 @default.
• W2319325812 creator A5054489358 @default.
• W2319325812 creator A5071319035 @default.
• W2319325812 creator A5073865202 @default.
• W2319325812 creator A5073985215 @default.
• W2319325812 creator A5084882022 @default.
• W2319325812 creator A5087341200 @default.
• W2319325812 date "2014-04-01" @default.
• W2319325812 modified "2023-10-17" @default.
• W2319325812 title "A 2-Stage, Single-Arm, Phase 2 Study of Epigallocatechin Gallate–Enriched Green Tea Drink as a Maintenance Therapy in Women With Advanced-Stage Ovarian Cancer" @default.
• W2319325812 doi "https://doi.org/10.1097/01.ogx.0000446909.04052.1e" @default.
• W2319325812 hasPublicationYear "2014" @default.
• W2319325812 type Work @default.
• W2319325812 sameAs 2319325812 @default.
• W2319325812 citedByCount "1" @default.
• W2319325812 countsByYear W23193258122019 @default.
• W2319325812 crossrefType "journal-article" @default.
• W2319325812 hasAuthorship W2319325812A5001534228 @default.
• W2319325812 hasAuthorship W2319325812A5011724082 @default.
• W2319325812 hasAuthorship W2319325812A5022422757 @default.
• W2319325812 hasAuthorship W2319325812A5023267102 @default.
• W2319325812 hasAuthorship W2319325812A5023514231 @default.
• W2319325812 hasAuthorship W2319325812A5033540995 @default.
• W2319325812 hasAuthorship W2319325812A5054489358 @default.
• W2319325812 hasAuthorship W2319325812A5071319035 @default.
• W2319325812 hasAuthorship W2319325812A5073865202 @default.
• W2319325812 hasAuthorship W2319325812A5073985215 @default.
• W2319325812 hasAuthorship W2319325812A5084882022 @default.
• W2319325812 hasAuthorship W2319325812A5087341200 @default.
• W2319325812 hasConcept C121608353 @default.
• W2319325812 hasConcept C126322002 @default.
• W2319325812 hasConcept C141071460 @default.
• W2319325812 hasConcept C143998085 @default.
• W2319325812 hasConcept C146357865 @default.
• W2319325812 hasConcept C150173356 @default.
• W2319325812 hasConcept C151730666 @default.
• W2319325812 hasConcept C2776694085 @default.
• W2319325812 hasConcept C2777511904 @default.
• W2319325812 hasConcept C2780427987 @default.
• W2319325812 hasConcept C2781100745 @default.
• W2319325812 hasConcept C29456083 @default.
• W2319325812 hasConcept C530470458 @default.
• W2319325812 hasConcept C535046627 @default.
• W2319325812 hasConcept C71924100 @default.
• W2319325812 hasConcept C86803240 @default.
• W2319325812 hasConceptScore W2319325812C121608353 @default.
• W2319325812 hasConceptScore W2319325812C126322002 @default.
• W2319325812 hasConceptScore W2319325812C141071460 @default.
• W2319325812 hasConceptScore W2319325812C143998085 @default.
• W2319325812 hasConceptScore W2319325812C146357865 @default.
• W2319325812 hasConceptScore W2319325812C150173356 @default.
• W2319325812 hasConceptScore W2319325812C151730666 @default.
• W2319325812 hasConceptScore W2319325812C2776694085 @default.
• W2319325812 hasConceptScore W2319325812C2777511904 @default.
• W2319325812 hasConceptScore W2319325812C2780427987 @default.
• W2319325812 hasConceptScore W2319325812C2781100745 @default.
• W2319325812 hasConceptScore W2319325812C29456083 @default.
• W2319325812 hasConceptScore W2319325812C530470458 @default.
• W2319325812 hasConceptScore W2319325812C535046627 @default.
• W2319325812 hasConceptScore W2319325812C71924100 @default.
• W2319325812 hasConceptScore W2319325812C86803240 @default.
• W2319325812 hasIssue "4" @default.
• W2319325812 hasLocation W23193258121 @default.
• W2319325812 hasOpenAccess W2319325812 @default.
• W2319325812 hasPrimaryLocation W23193258121 @default.
• W2319325812 hasRelatedWork W2013577284 @default.
• W2319325812 hasRelatedWork W2065800215 @default.
• W2319325812 hasRelatedWork W2066912469 @default.
• W2319325812 hasRelatedWork W2133480631 @default.
• W2319325812 hasRelatedWork W2944256364 @default.
• W2319325812 hasRelatedWork W3027148523 @default.
• W2319325812 hasRelatedWork W3097676887 @default.
• W2319325812 hasRelatedWork W4255034425 @default.
• W2319325812 hasRelatedWork W59268075 @default.
• W2319325812 hasRelatedWork W74951144 @default.
• W2319325812 hasVolume "69" @default.
• W2319325812 isParatext "false" @default.
• W2319325812 isRetracted "false" @default.
• W2319325812 magId "2319325812" @default.
• W2319325812 workType "article" @default.